Probes for radiotheranostics could
be produced by introducing radionuclides
with similar chemical characteristics into the same precursors. We
recently developed an 211At-labeled RGD peptide and a corresponding
radioiodine-labeled RGD peptide. Both labeled peptides accumulated
in large quantities in the tumor with similar biodistribution, demonstrating
their usefulness for radiotheranostics. In this study, we hypothesized
that probes for radiotheranostics combined with multiradionuclides,
such as 68Ga and 211At, have useful clinical
applications. New radiolabeled RGD peptide probes were synthesized
via a molecular design approach, with two labeling sites for metal
and halogen. These probes were evaluated in biodistribution experiments
using tumor-bearing mice. [67Ga]Ga-DOTA-c[RGDf(4-I)K] ([67Ga]4), Ga-DOTA-[125I]c[RGDf(4-I)K]
([125I]4), and Ga-DOTA-[211At]c[RGDf(4-At)K]
([211At]7) showed similar biodistribution,
with high and equivalent accumulation in tumors. These results indicate
the usefulness of these probes in radiotheranostics with multiradionuclides,
such as a radiometal and a radiohalogen, and they could contribute
to a personalized medicine regimen.
We recently developed 125I- and 211At-labeled monomer RGD peptides using a novel radiolabeling method. Both labeled peptides showed high accumulation in the tumor and exhibited similar biodistribution, demonstrating their usefulness for radiotheranostics. This study applied the labeling method to a dimer RGD peptide with the aim of gaining higher accumulation in tumor tissues based on improved affinity with αvβ3 integrin. We synthesized an iodine-introduced dimer RGD peptide, E[c(RGDfK)] (6), and an 125/131I-labeled dimer RGD peptide, E[c(RGDfK)]{[125/131I]c[RGDf(4-I)K]} ([125/131I]6), and evaluated them as a preliminary step to the synthesis of an 211At-labeled dimer RGD peptide. The affinity of 6 for αvβ3 integrin was higher than that of a monomer RGD peptide. In the biodistribution experiment at 4 h postinjection, the accumulation of [125I]6 (4.12 ± 0.42% ID/g) in the tumor was significantly increased compared with that of 125I-labeled monomer RGD peptide (2.93 ± 0.08% ID/g). Moreover, the accumulation of [125I]6 in the tumor was greatly inhibited by co-injection of an excess RGD peptide. However, a single injection of [131I]6 (11.1 MBq) did not inhibit tumor growth in tumor-bearing mice. We expect that the labeling method for targeted alpha therapy with 211At using a dimer RGD peptide could prove useful in future clinical applications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.